Study of Pharmacology of 17-OHPC in Pregnancy

Completed · Phase 2

Conditions studied: Pregnancy

In brief

We are examining the pharmacology of 17-OHPC in pregnancy, specifically between the second and third trimesters.

Key facts

Study ID

NCT00409825

Run by

University of Pittsburgh

People needed

61

Starts

2006-03-01

Expected to finish

2014-02-01

Last updated by the study team

2015-02-27

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Singleton gestation prior to 20 0/7 weeks gestation
• Planning to receive or receiving 17-OHPC (250 mg IM weekly)
• Previous history of preterm birth
• Able to give consent

You may not qualify if…

• Fetal demise, anomaly, or growth restriction
• Hepatic or renal dysfunction
• Placental previa or abruptio placenta
• Polyhydramnios/oligohydramnios
• Short cervix or planned cerclage
• Chronic use of steroids, antiepileptics, antihypertensives, SSRS, street drugs
• Participation in another interventional study that influences gestational age at delivery
• Heparin treatment of known platelet count <100,000/mm3 (because of contraindication to intra-muscular injections)

Where it is running

• Georgetown University — Washington D.C., District of Columbia, United States
• Magee-Womens Hospital of University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States
• University of Texas — Galveston, Texas, United States
• University of Washington — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.